Literature DB >> 27016011

Polymorphous low-grade adenocarcinoma: A Danish national study.

Mohammad Talal Elhakim1, Helle Breinholt1, Christian Godballe1, Lisbeth Juhler Andersen2, Hanne Primdahl3, Claus A Kristensen4, Kristine Bjørndal5.   

Abstract

OBJECTIVES: To present a national series of polymorphous low-grade adenocarcinoma (PLGA) patients, including survival rates and an analysis of prognostic factors.
MATERIALS AND METHODS: By merging three Danish nationwide registries, 73 patients diagnosed with PLGA from 1990 to 2005 were identified. Histological slides were reviewed and data concerning demographics, tumour site, clinical stage, treatment profiles and follow-up were retrieved. Survival estimates and prognostic factors were evaluated by comparing Kaplan-Meier plots using the Mantel-Haenszel log-rank test.
RESULTS: Of the 73 patients, 47 (64%) were female. Median age was 58years. The most common location was the palate (73%). Median latency was five months. Recurrence was seen in 13% of patients. Overall survival (OS), disease-specific survival (DSS) and recurrence-free survival (RFS) rates after 10years were 73%, 99% and 83%, respectively. Univariate analyses suggested that free resection margins significantly improve RFS.
CONCLUSION: PLGA usually has an excellent survival outcome even in cases of advanced stage disease and locoregional recurrence. Primary choice of treatment should be complete surgical excision. Although there is no convincing evidence for the efficacy of adjuvant radiotherapy, it should still be considered, particularly in cases of involved resection margins and advanced stage disease. Late recurrences are common and respond well to salvage therapy.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  National; Oral cancer; Polymorphous low-grade adenocarcinoma; Prognostic factors; Survival

Mesh:

Year:  2016        PMID: 27016011     DOI: 10.1016/j.oraloncology.2016.02.005

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  7 in total

1.  Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Oropharynx.

Authors:  William H Westra; James S Lewis
Journal:  Head Neck Pathol       Date:  2017-02-28

2.  Polymorphous adenocarcinoma of salivary glands.

Authors:  Ximena Mimica; Nora Katabi; Marlena R McGill; Ashley Hay; Daniella Karassawa Zanoni; Jatin P Shah; Richard J Wong; Marc A Cohen; Snehal G Patel; Ian Ganly
Journal:  Oral Oncol       Date:  2019-06-07       Impact factor: 5.337

3.  Advancing toward a molecular characterization of polymorphous low grade adenocarcinoma.

Authors:  Piotr T Wysocki; William H Westra; David Sidransky; Mariana Brait
Journal:  Oral Oncol       Date:  2017-09-20       Impact factor: 5.337

4.  Predictors of Outcome in the Phenotypic Spectrum of Polymorphous Low-grade Adenocarcinoma (PLGA) and Cribriform Adenocarcinoma of Salivary Gland (CASG): A Retrospective Study of 69 Patients.

Authors:  Bin Xu; Amandeep Aneja; Ronald Ghossein; Nora Katabi
Journal:  Am J Surg Pathol       Date:  2016-11       Impact factor: 6.394

Review 5.  Polymorphous adenocarcinoma of the salivary glands: reappraisal and update.

Authors:  Vincent Vander Poorten; Asterios Triantafyllou; Alena Skálová; Göran Stenman; Justin A Bishop; Esther Hauben; Jennifer L Hunt; Henrik Hellquist; Simon Feys; Remco De Bree; Antti A Mäkitie; Miquel Quer; Primož Strojan; Orlando Guntinas-Lichius; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-05-14       Impact factor: 2.503

Review 6.  Polymorphous Adenocarcinoma.

Authors:  Nora Katabi; Bin Xu
Journal:  Surg Pathol Clin       Date:  2021-01-05

7.  Diagnostic discrepancy in second opinion reviews of primary epithelial neoplasms involving salivary gland: An 11-year experience from a tertiary referral center focusing on useful pathologic approaches and potential clinical impacts.

Authors:  Bin Xu; Ronald Ghossein; Alan Ho; Kartik Viswanathan; Anjanie Khimraj; Maelle Saliba; Jennifer R Cracchiolo; Nora Katabi
Journal:  Head Neck       Date:  2021-04-24       Impact factor: 3.821

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.